GS-5829 + Exemestane + Fulvestrant
Phase 1/2Terminated 1 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Estrogen Receptor Positive HER2- Breast Cancer
Conditions
Advanced Estrogen Receptor Positive HER2- Breast Cancer
Trial Timeline
Jan 10, 2017 → Jul 19, 2018
NCT ID
NCT02983604About GS-5829 + Exemestane + Fulvestrant
GS-5829 + Exemestane + Fulvestrant is a phase 1/2 stage product being developed by Gilead Sciences for Advanced Estrogen Receptor Positive HER2- Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02983604. Target conditions include Advanced Estrogen Receptor Positive HER2- Breast Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Estrogen Receptor Positive HER2- Breast Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02983604 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Advanced Estrogen Receptor Positive HER2- Breast Cancer